Structural Biology meets Drug Discovery in this Cool Company By Clara Rodríguez Fernández 1 minutemin November 25, 2016 -Updated: onJune 22, 2022 1 minutemin Share WhatsApp Twitter Linkedin Email Newsletter Signup - Under Article / In Page"*" indicates required fieldsNameThis field is for validation purposes and should be left unchanged.Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*Company name*Job title*Business email* After an amazing day in Paris for Labiotech Refresh, we head back to Germany to meet Proteros. The company is working non-stop to provide drug candidates against some of the hottest targets in biotech.City: Munich, GermanyFounded: 1999Employees: 80+Financial data: The company just announced a €157M ($167M) deal with MSDTorsten Neuefeind, CEOMission: Proteros’ expertise in structural biology has led the company to build a strong pipeline focused on oncology and neurology. Its drugs are directed at epigenetic targets, kinases, and G-protein-coupled receptors (GPCRs), three hot areas in the biotech industry.Comment: The new deal with MSD comes as another great collaboration for Proteros on top of already established ones with top level players Janssen and Bayer. Unfortunately, the company keeps secret most details of these partnerships, so it’s difficult to evaluate its impact.Featured image: Labiotech map Organoids in cancer research: Paving the way for faster drug development across cancer indications This webinar explores how patient-derived organoids (PDOs) are redefining oncology research. Discover how advanced, well-characterized models empower researchers to streamline candidate selection, accelerate orphan drug programs, and deliver transformative therapies to patients faster than ever. Watch now Explore other topics: CancerDrug discoveryepigeneticsGermanyGPCR ADVERTISEMENT